Portal de investigação
Pthological rola of urocortin-2 in pulmonaryn hypertension - therapeutic implications
Dados básicos
- Código:
- Estudo Clínico Académico
- Protocolo:
- Estudo Clínico Académico
- EUDRACT:
- NCT:
- Centro:
- Dotação:
- Ano de início:
- 2020
- Ano de conclusão:
Objectivos do projeto
Estudos Observacionais (STROBE statement); Natureza do Promotor: Academia – Tipo não comercial – Iniciativa do Investigador; Tipo de Centro: Unicêntrico – Cuidados Secundários
Documentos
- Não há documentos
Participantes
Unidades de investigação
Stakeholders - Promotores
Outputs do ensaio clínico
An Overview of Circulating Pulmonary Arterial Hypertension Biomarkers
Santos-Gomes, J; (...); Bras-Silva, C
Review. 10.3389/fcvm.2022.924873. 2022
Candidate microRNAs as prognostic biomarkers in heart failure: A systematic review
Figueiredo, R; (...); Brás-Silva, C
Review. 10.1016/j.repc.2021.03.020. 2022
Editorial: Therapeutics in pulmonary arterial hypertension
Adao, Rui; (...); Bras-Silva, Carmen
Editorial Material. 10.3389/fcvm.2024.1463305. 2024
Efficacy of the thromboxane receptor antagonist NTP42 alone, or in combination with sildenafil, in the sugen/hypoxia-induced model of pulmonary arterial hypertension
Mulvaney, EP; (...); Kinsella, BT
Article. 10.1016/j.ejphar.2020.173658. 2020
Emerging Roles of Micrornas in Veterinary Cardiology
Reis-Ferreira, A; (...); Fontes-Sousa, AP
Review. 10.3390/vetsci9100533. 2022
Heart Failure with Preserved Ejection Fraction: a Pharmacotherapeutic Update
Vaz Salvador, P; (...); Brás-Silva, C
Review. 10.1007/s10557-021-07306-8. 2023
Kcnk3 dysfunction exaggerates the development of pulmonary hypertension induced by left ventricular pressure overload
Lambert, M; (...); Antigny, F
Article. 10.1093/cvr/cvab016. 2021
NTP42 alleviates experimental pulmonary arterial hypertension and promotes beneficial right ventricular adaptation, preserving right heart function
Mulvaney, E.; (...); Kinsella, B. T.
Meeting Abstract. 10.1183/13993003.congress-2022.1195. 2022
Pathophysiological and therapeutic implications of urocortin-2 in heart failure with preserved ejection fraction
Adao, R; (...); Bras-Silva, C
Meeting Abstract. 2022
Physiological and pathophysiological roles of the KCNK3 potassium channel in the pulmonary circulation and the heart
Willer, ASM; (...); Antigny, F
Review. 10.1113/JP284936. 2023
Pulmonary Valve Replacement: A New Paradigm with Tissue Engineering
Almeida-Pintoa, R; (...); Adao, R
Review. 10.1016/j.cpcardiol.2022.101212. 2023
The Ketone Bridge Between the Heart and the Bladder: How Fast Should We Go?
Faria-Costa, Gabriel; (...); Charrua, Ana
Article. 10.5213/inj.2346250.125. 2024
The thromboxane receptor antagonist NTP42 promotes beneficial adaptation and preserves cardiac function in experimental models of right heart overload
Mulvaney, EP; (...); Kinsella, BT
Article. 10.3389/fcvm.2022.1063967. 2022
The Thromboxane Receptor Antagonist NTP42 Promotes Beneficial Right Ventricular Adaptation and Preserves Right Heart Function in the Pulmonary Artery Banding Model of Pressure Overload
Mulvaney, E.; (...); Kinsella, B. T.
Meeting Abstract. 2022
Therapeutic Approaches in Pulmonary Arterial Hypertension with Beneficial Effects on Right Ventricular Function-Preclinical Studies
Balsa, A, Adao, R, Brás-Silva, C
Review. 10.3390/ijms242115539. 2023
Therapeutic effects of nebulization-based delivery of anti-miR-146a in experimental pulmonary arterial hypertension
Santos Peixoto Gomes, J.; (...); Bras-Silva, C.
Meeting Abstract. 2022
Urocortin-2 as a novel biomarker of clinical deterioration in HFpEF: a prospective cohort study
Ines Vasconcelos, I.; (...); Bras-Silva, C.
Meeting Abstract. 2024
Urocortin-2 in Acute Heart Failure: Role as a Marker of Volume Overload and Pulmonary Hypertension
Pintalhao, M; (...); Bras-Silva, C
Review. 10.1016/j.cpcardiol.2021.100860. 2022
Urocortins as biomarkers in cardiovascular disease
Vasconcelos, I; (...); Brás-Silva, C
Review. 10.1042/CS20210732. 2022
